Next 10 |
MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome, Inc. (Nasdaq: IMNM). As per the ...
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors. A total of 156 ...
International Zeolite Corp. (IZCFF) is expected to report for Q2 2024 International Stem Cell Corporation (ISCO) is expected to report for Q4 2023 Zivo Bioscience Inc. (ZIVO) is expected to report for Q4 2023 Hongchang International Co Ltd Com (New) (HCIL) is expected to report for Q4...
2024-02-06 08:14:45 ET More on Advaxis, Immunome, etc. Immunome: Why It Has Doubled Over The Last Month Immunome a new outperform at Wedbush on cancer platforms Historical earnings data for Advaxis Financial information for Advaxis Seeking Alphaȁ...
– AL102 is a small molecule gamma secretase inhibitor with a differentiated clinical profile – Immunome , Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced that it entered into...
BOTHELL, Wash. and MONMOUTH JUNCTION, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Immunome , Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced that it entered into a definitive asset purchase agreement ...
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to AL102, a Gamma Secretase Inhibi...
CGG ADR (CGGYY) is expected to report for quarter end 2023-09-30 ATI Physical Therapy Inc. Class A (ATIP) is expected to report $-4.08 for Q3 2023 Riot Platforms Inc. (RIOT) is expected to report $-0.29 for Q3 2023 Bain Capital Specialty Finance Inc. (BCSF) is expected to report $0.57...
FMC Corporation (FMC) is expected to report $0.45 for Q3 2023 NCS Multistage Holdings Inc. (NCSM) is expected to report $2.59 for Q3 2023 Third Century Bancorp (TDCB) is expected to report for Q3 2023 ZoomInfo Technologies Inc. (ZI) is expected to report $0.15 for Q3 2023 Matson I...
Grandsouth Bancorporation (GRRB) is expected to report for quarter end 2023-09-30 Cadence Bank (CADE) is expected to report $0.56 for Q3 2023 Enterprise Financial Services Corporation (EFSC) is expected to report $1.24 for Q3 2023 Blackhawk Bancorp Inc. (BHWB) is expected to report fo...
News, Short Squeeze, Breakout and More Instantly...
MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome, Inc. (Nasdaq: IMNM). As per the ...
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors. A total of 156 ...
International Zeolite Corp. (IZCFF) is expected to report for Q2 2024 International Stem Cell Corporation (ISCO) is expected to report for Q4 2023 Zivo Bioscience Inc. (ZIVO) is expected to report for Q4 2023 Hongchang International Co Ltd Com (New) (HCIL) is expected to report for Q4...